Skip to main content

Obesity management approaches

In this episode Ole Schmiedel discusses Mounjaro, a new weight loss drug, with a focus on its mechanism of action, practical use, side effects, nutritional considerations, and long-term safety. The conversation provides insights into how Mounjaro differs from previous GLP-1 receptor agonists, expected weight loss outcomes, and the importance of monitoring patients while on the medication.

Topics

  1. Play now
  2. Play now
  3. Play now
  4. Play now
  5. Play now
  6. Play now
  7. Play now
  8. Play now
  9. Play now
  10. Play now
  11. Play now
  12. Play now
  13. Play now
  14. Play now

Take home messages

Presenter

Ole Schmiedel

Consultant in Endocrinology, Diabetes, and General Internal Medicine

Ole is a consultant in Endocrinology, Diabetes, and General Internal Medicine at Auckland District Health Board. He is the Service Clinical Director of Auckland Diabetes Centre. He qualified in medicine from Humboldt University, Berlin, Germany in 1997 and trained in endocrinology and diabetes at Cardiff University, Wales, UK. In 2009 he completed his specialist training in the UK and was awarded the Medical Doctorate for his work in the area of diabetes and microvascular complications.

Ole has been working as a physician and endocrinologist in New Zealand since 2009, and has expertise in all areas of diabetes management, with particular interests in type 2 diabetes, obesity, and medical weight management. In addition, he specialises in all areas of endocrinology including thyroid, adrenal, PCOS, bone health, male and female hormones.

Recognition of Learning Activities RNZCGP Logo

Don't forget to log your time with The Royal New Zealand College of General Practitioners portal for recognition of learning activities.

Log your CPD

The Goodfellow Unit podcast is funded in part by the Royal New Zealand College of General Practitioners.

www.rnzcgp.org.nz